Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal C3B Primary Antibody pour IHC (fro), WB - ABIN2477797
Hallström, Nordström, Tan, Manolov, Lambris, Isenman, Zipfel, Blom, Riesbeck: Immune evasion of Moraxella catarrhalis involves ubiquitous surface protein A-dependent C3d binding. dans Journal of immunology (Baltimore, Md. : 1950) 2011
Anti-HLA class I (Montrer MICA Anticorps) and class II C3d (Montrer C3 Anticorps)-binding donor-specific antibodies carried a twofold and 1.5-fold increased risk of kidney graft loss, respectively.
Here we have shown for the first time, that ligand- or insulin (Montrer INS Anticorps)-mediated activation of PPARgamma (Montrer PPARG Anticorps) in human hepatoma cell line HepG2 causes the downregulation of C3 gene expression and protein secretion
Single Nucleotide Polymorphism rs11569514 in C3 and haplotypes of C3 variants were associated with schizophrenia in a Han Chinese population.
C3F (Montrer LPCAT3 Anticorps) polymorphism is associated with viral infections and protection from rejection after liver transplantation.
Pra1 (Montrer RABAC1 Anticorps) targets C3 by cleaving C3 at a unique site. This inhibited effector function of the activation fragments. The newly formed C3a (Montrer C3 Anticorps)-like peptide lacked the C-terminal arginine residue needed for C3a (Montrer C3 Anticorps)-receptor binding and activation. Pra1 (Montrer RABAC1 Anticorps) also bound to C3a (Montrer C3 Anticorps) and C3b generated by human convertases and blocked their effector functions, C3a (Montrer C3 Anticorps) binding to human C3a (Montrer C3 Anticorps) receptor, C3 antifungal activity, and C3b deposition.
data provide the first evidence that T17M rhodopsin (Montrer RHO Anticorps) mutant disrupts C3 secretion via the induction of ROS (Montrer ROS1 Anticorps) and the suppression of TWIST1 (Montrer TWIST1 Anticorps).
The complement activation factors Bb, C3a, C5a, and MAC were increased significantly in early-onset severe pre-eclampsia (EOSPE) (all P<.01) and late-onset severe pre-eclampsia (LOSPE). (P value: .027, <.001, .001, and <.001, respectively) compared with E/L-control. C1q and C4d were increased significantly in LOSPE (P value: .003 and .014, respectively) compared with L-control.
This study enclosed strong synergistic association of risk genotypes of C3 and CFH (Montrer CFH Anticorps) Y402H with AMD (Montrer AMD1 Anticorps). We also revealed synergistic influence of CCL2 (Montrer CCL2 Anticorps)-2518 and the at-risk genotype of the C3 in AMD (Montrer AMD1 Anticorps) with an estimated AP = 50.9% (adjusted AP = 24.7%). Present findings show that CCL2 (Montrer CCL2 Anticorps)-2518 polymorphism is not an innocent bystander (Montrer SEPT1 Anticorps) in AMD (Montrer AMD1 Anticorps) susceptibility when combined with the at-risk genotype of C3 (R102G).
Our study shows C3 to be a relatively strong susceptibility gene for advanced-type-AMD (Montrer AMD1 Anticorps) (exudative-and-geographic-atrophy) in an Iranian population.
BBB (Montrer ALMS1 Anticorps) disruption is present in ACS (Montrer PLA2G15 Anticorps), and elevated levels of IL-6 (Montrer IL6 Anticorps) and C3 in CSF (Montrer CSF2 Anticorps) in diffuse NPSLE
Complement component C3 plays a central role in the activation of complement system. Its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacterial infection.
C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1
, C3a anaphylatoxin
, acylation-stimulating protein cleavage product
, complement C3
, complement component C3
, complement component C3a
, complement component C3b